Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Wave Life SciencesWVE +2.36%60 Earnings Yield (Joel Greenblatt) % is -32.26% as of Jun. 2026. GuruFocus rates WVE with a GF Score™ of 60/100 and a GF Value™ of $4.00 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,343 Biotechnology companies, Wave Life Sciences ranks worse than 76.84% on this metric.
Wave Life Sciences's Enterprise Value for the quarter that ended in Jun. 2026 was $675.93 Mil.
Wave Life Sciences's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was $-217.92 Mil. Wave Life Sciences's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2026 was -32.26%.
The historical rank and industry rank for Wave Life Sciences's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
WVE'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3543.48 Med: -21.54 Max: 8100.51
Current: -35.59
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Wave Life Sciences was 8100.51%. The lowest was -3543.48%. And the median was -21.54%.
WVE's Earnings Yield (Joel Greenblatt) % is ranked worse than 76.84% of 1343
companies
in the Biotechnology industry
Industry Median: -9.92
vs WVE: -35.59
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Wave Life Sciences's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Wave Life Sciences (NAS:WVE) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Wave Life Sciences Earnings Yield (Joel Greenblatt) % Related Terms
Wave Life Sciences Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Wave Life Sciences's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wave Life Sciences Earnings Yield (Joel Greenblatt) % Chart
For the Biotechnology subindustry, Wave Life Sciences's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wave Life Sciences Earnings Yield (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Wave Life Sciences's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Wave Life Sciences's Earnings Yield (Joel Greenblatt) % falls into.
Wave Life Sciences Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Wave Life Sciencess Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
Wave Life Sciences's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-217.92 Mil.
What does a Earnings Yield (Joel Greenblatt) % of -32.26% mean?
Wave Life Sciences (WVE) has a Earnings Yield (Joel Greenblatt) % of -32.26% as of Jun. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Wave Life Sciences and its competitors. According to the industry distribution chart, Wave Life Sciences ranks #1032 out of 1343 companies in the Biotechnology industry, placing it in the top 76.8%.
Is Wave Life Sciences' Earnings Yield (Joel Greenblatt) % too high?
Wave Life Sciences' current Earnings Yield (Joel Greenblatt) % is -32.26%. Based on the distribution chart, Wave Life Sciences ranks #1032 out of 1343 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Wave Life Sciences has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Wave Life Sciences' Earnings Yield (Joel Greenblatt) % compare to FBRX and SVRA?
According to the Biotechnology industry distribution chart, Wave Life Sciences ranks #1032 out of 1343 companies for Earnings Yield (Joel Greenblatt) %. This places Wave Life Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Biotechnology company?
A good Earnings Yield (Joel Greenblatt) % depends on the Biotechnology industry context. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Wave Life Sciences and its competitors. Wave Life Sciences's current Earnings Yield (Joel Greenblatt) % is -32.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wave Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Wave Life Sciences (WVE) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.00, compared to a current price of $5.37 — trading 34.3% above its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is -32.26%. Wave Life Sciences' overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Wave Life Sciences (WVE), the current Earnings Yield (Joel Greenblatt) % is -32.26% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wave Life Sciences (WVE) Overvalued in 2026?
Based on GuruFocus' analysis, Wave Life Sciences stock appears to be overvalued.
The current stock price of $5.37 is trading 34.3% above its estimated GF Value™ of $4.00.
GuruFocus considers Wave Life Sciences to be Significantly Overvalued.
Key valuation signals for WVE:
Earnings Yield (Joel Greenblatt) %: -32.26%
GF Value™: $4.00 vs. price of $5.37 (34.3% above fair value)
No single metric tells the full story. See the WVE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
60GF Score
Get the complete analysis for WVE
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WVE has been successfully added to your 
